Skip to main content

Table 1 COPD/CB patient characteristics at baseline and medication during the year before baseline

From: Exacerbations and healthcare resource utilization among COPD patients in a Swedish registry-based nation-wide study

Patient characteristics

Female

N = 47,487 (53.6%)

Male

N = 41,061 (46.4%)

P-value

Total

N = 88,548 (100%)

Age, years

71.9 ± 11.1

72.3 ± 10.5

<0.001

72.1 ± 10.8

Time since COPD/CB diagnosis, years

4.5 ± 3.2

4.3 ± 3.2

<0.001

4.4 ± 3.2

COPD medicationa

 SABA

1299 (2.7)

957 (2.3)

<0.001

2256 (2.5)

 SAMA

1025 (2.2)

905 (2.2)

0.660

1930 (2.2)

 SABA + SAMA

353 (0.7)

260 (0.6)

0.054

613 (0.7)

 ICS only

3510 (7.4)

2561 (6.2)

<0.001

6071 (6.9)

 LABA only

667 (1.4)

562 (1.4)

0.670

1229 (1.4)

 LAMA only

2687 (5.7)

2504 (6.1)

0.006

5191 (5.9)

 ICS + LABA

12,275 (25.8)

9644 (23.5)

<0.001

21,919 (24.8)

 ICS + LAMA

1181 (2.5)

913 (2.2)

0.011

2094 (2.4)

 LABA + LAMA

434 (0.9)

369 (0.9)

0.839

803 (0.9)

 ICS + LABA + LAMA

12,197 (25.7)

9553 (23.3)

<0.001

21,750 (24.6)

No COPD medication

11,859 (25.0)

12,833 (31.3)

<0.001

24,692 (27.9)

Other medications

 Beta blockers

16,375 (34.5)

16,430 (40.0)

<0.001

32,805 (37.0)

 ACE inhibitors

11,757 (24.8)

13,309 (32.4)

<0.001

25,066 (28.3)

 Calcium blockers

10,423 (21.9)

8808 (21.5)

0.074

19,231 (21.7)

 Angiotensin-receptor blockers

6106 (12.9)

5247 (12.8)

0.731

11,353 (12.8)

 Statins

13,105 (27.6)

14,327 (34.9)

<0.001

27,432 (31.0)

  1. Numbers presented as n (%), or mean ± SD. P-value for difference between genders
  2. Abbreviations: COPD Chronic obstructive pulmonary disease, CB Chronic bronchitis, SD Standard deviation, SABA Inhaled short-acting beta-2-agonist, SAMA Inhaled short-acting muscarinic antagonist, ICS Inhaled glucocorticoids, LABA Long-acting beta agonist, LAMA Long-acting muscarinic antagonist, ACE Angiotensin-converting enzyme
  3. aResults for SABA and/or SAMA are reported as monotherapy without any other COPD medication allowed. Use of rescue medication (SABA and/or SAMA) was ignored when evaluating usage percentages of other COPD medication options. ATC codes are listed in Additional file 1: Table S1